10 results
8-K
EX-99.1
XLO
Xilio Therapeutics Inc
1 Apr 24
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
4:15pm
clinical data package for XTX301, Gilead can elect to transition responsibilities for the development and commercialization of XTX301 to Gilead, subject
8-K
EX-99.1
pf3u d0wu
28 Mar 24
Entry into a Material Definitive Agreement
7:55am
8-K
ifnmytllu2ha
28 Mar 24
Entry into a Material Definitive Agreement
7:55am
8-K
EX-99.2
9jpf to33zvgjsv2t1
28 Mar 24
Entry into a Material Definitive Agreement
7:55am
DEF 14A
t8l3smp
26 Apr 22
Definitive proxy
4:05pm
- Prev
- 1
- Next